Sarepta Therapeutics Inc’s recent filing unveils that its Chief Financial Officer Estepan Ian Michael unloaded Company’s shares for reported $0.82 million on Aug 30 ’24. In the deal valued at $137.36 per share,5,985 shares were sold. As a result of this transaction, Estepan Ian Michael now holds 33,946 shares worth roughly $4.24 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Estepan Ian Michael bought 5,985 shares, generating $822,130 in total proceeds.
Before that, Chambers Michael Andrew bought 37,038 shares. Sarepta Therapeutics Inc shares valued at $4,955,728 were divested by the Director at a price of $133.80 per share. As a result of the transaction, Chambers Michael Andrew now holds 284,034 shares, worth roughly $35.51 million.
Jefferies initiated its Sarepta Therapeutics Inc [SRPT] rating to a Buy in a research note published on October 21, 2024; the price target was $165. RBC Capital Mkts also remained covering SRPT and has increased its forecast on July 29, 2024 with a “an Outperform” recommendation from previously “Sector perform” rating. Citigroup revised its rating on June 26, 2024. It rated SRPT as “a Neutral” which previously was an “a Buy”.
Price Performance Review of SRPT
On Tuesday, Sarepta Therapeutics Inc [NASDAQ:SRPT] saw its stock jump 1.58% to $125.01. Over the last five days, the stock has lost -3.99%. Sarepta Therapeutics Inc shares have risen nearly 29.64% since the year began. Nevertheless, the stocks have risen 60.25% over the past one year. While a 52-week high of $173.25 was reached on 06/21/24, a 52-week low of $75.85 was recorded on 01/05/24. SMA at 50 days reached $126.86, while 200 days put it at $130.59.
Levels Of Support And Resistance For SRPT Stock
The 24-hour chart illustrates a support level at 122.38, which if violated will result in even more drops to 119.74. On the upside, there is a resistance level at 126.45. A further resistance level may holdings at 127.88. The Relative Strength Index (RSI) on the 14-day chart is 46.43, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.76, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 67.62%. Stochastics %K at 18.25% indicates the stock is a buying.
How much short interest is there in Sarepta Therapeutics Inc?
A steep rise in short interest was recorded in Sarepta Therapeutics Inc stocks on 2024-10-15, dropping by -0.49 million shares to a total of 5.66 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-13 was 6.15 million shares. There was a decline of -8.66%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on May 31, 2024 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $157 price target.
